Varenicline for cognitive impairment in people with schizophrenia: systematic review and meta-analysis.
Background: People with schizophrenia frequently have cognitive dysfunction, which does not respond to pharmacological interventions. Varenicline has been identified as a potential treatment option for nicotinic receptor dysfunction with a potential to treat cognitive impairment in schizophrenia. Me...
| Publicado en: | Psychopharmacology Vol. 237; no. 1; pp. 11 - 20 |
|---|---|
| Autores principales: | , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Jan2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |